Moreover, it has been reported that T cells with chimeric antigen receptors have the potential to treat numerous types of cancers by targeting CD19, and down-regulation of CD19 expression by T cells with chimeric antigen receptors contributes to elimination of B cells, thereby impeding development and progression of pancreatic cancer (Morello et al., 2016; Chen et al., 2018; Sun et al., 2018; He et al., 2020; Ko et al., 2020). This evidence concerns the gene CD19 and pancreatic neoplasm.